



Review Article

<http://wjpn.ssu.ac.ir>

Dynamic Extracellular Matrix Remodeling and Immune Reprogramming in the Postpartum Mammary Gland: Implications for Maternal Health and Breast Cancer Risk

Samane Heydari^{1*}, Sadegh Safaei²

¹ Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

² Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Received: 20 May 2026

Revised: 31 May 2026

Accepted: 13 June 2026

ARTICLE INFO

Corresponding author:

Samane Heydari

Email:

samaneh.heidari90@gmail.com

Keywords:

Breast Neoplasms,
Mammary Glands,
Extracellular Matrix,
Tumor Microenvironment,
Collagen

ABSTRACT

The mammary gland is a uniquely dynamic organ, undergoing profound structural and functional transformations throughout the pregnancy-lactation-involution cycle. These changes are orchestrated by a complex interplay between systemic hormones and the local microenvironment. Recent studies identify the extracellular matrix (ECM) and the innate immune landscape as critical determinants of both physiological tissue homeostasis and pathological progression. Postpartum breast cancer (PPBC), defined as breast cancer diagnosed within ten years following childbirth, represents a distinct clinical entity characterized by increased aggressiveness, higher metastatic potential, and poor prognosis. This review provides a comprehensive synthesis of recent updates in mammary gland biology, focusing on the triphasic pattern of collagen regulation, the role of matrix metalloproteinases (MMPs) and lysyl oxidase (LOX) in tissue remodeling, and the emergence of an immunosuppressive "wound-healing" environment during involution. We explore molecular regulatory nodes, including microRNAs and calpains, and the impact of environmental exposures on breast tissue composition. By integrating data derived from high-resolution spatial profiling and single-cell transcriptomic analyses, this article aims to provide an understanding of how the postpartum mammary microenvironment supports tumorigenesis, highlighting potential biomarkers and therapeutic targets to improve maternal health outcomes.

© 2025, Shahid Sadoughi University of Medical Sciences. This is an open access article under the Creative Commons Attribution 4.0 International License.

Introduction

Breast cancer (BC) remains the most prevalent malignancy and the primary cause of cancer-related mortality among women worldwide¹. A well-established epidemiological paradox exists regarding parity: while a full-term pregnancy confers long-term protection against lifetime breast cancer risk, it is accompanied by a transient but significant increase in risk in the immediate years following childbirth, a phenomenon known as the "postpartum paradox"². This window of vulnerability is increasingly critical in modern clinical practice as trends in delayed childbearing continue to rise, with the average age of first-time mothers frequently extending into the late thirties and early forties³.

Postpartum breast cancer (PPBC) is defined variably across studies, but most consensus guidelines use a window of 5 to 10 years following the most recent childbirth; some studies restrict the postpartum interval to 2–5 years, while others extend it to 10 years. This variability reflects differences in the latency of involution-associated risk and the study populations examined. Regardless of the exact interval, PPBC is no longer viewed merely as a temporal classification. It is now recognized as a biologically distinct and clinically aggressive subtype⁴. Studies comparing BC in parous women to age-matched nulliparous cohorts reveal that PPBC is associated with more aggressive pathologic features, a higher incidence of triple-negative breast cancer (TNBC), and a significantly higher rate of distant metastasis⁵. The aggressive phenotype of PPBC is thought to be largely driven by the pro-tumorigenic microenvironment that arises during the transition from a lactating to a post-weaning state, a process known as mammary involution. However, the vast majority of evidence linking involution to tumor progression derives from rodent models; direct causal evidence in humans remains limited, and the translational relevance of findings from acute, synchronized weaning models to the more gradual, heterogeneous human involution

process requires cautious interpretation⁶.

During involution, the mammary gland undergoes one of the most dramatic physiological remodeling events in adult mammalian biology⁷. Upon weaning, the cessation of milk removal triggers massive programmed cell death of the secretory epithelium, coupled with a total architectural reorganization of the stroma⁸. This process involves the recruitment of specialized immune cells and extensive extracellular matrix (ECM) remodeling that closely mirrors a chronic wound-healing response⁹. Emerging evidence suggests a model in which an "involution-like" ECM signature and an immunosuppressive, exhausted T-cell milieu act as dual drivers of PPBC progression; this remains a leading hypothesis that requires further validation in human cohorts^{10, 11}. This review will explore these dynamics in depth, providing an expert-level synthesis of how reproductive history shapes the landscape of maternal health and cancer risk.

Physiological States and the Triphasic Mammary Cycle

The mammary gland is characterized by its extraordinary plasticity, undergoing orchestrated cycles of proliferation, differentiation, and regression⁷. This triphasic cycle is governed by systemic endocrine signaling and reciprocal local crosstalk within the stroma (Table 1).

Pregnancy (The Expansion and Preparation Phase): During pregnancy, the mammary epithelium receives signals from systemic hormones, primarily estrogen and progesterone, to proliferate rapidly¹². This phase, termed alveologenesis, is characterized by extensive branching and the formation of secretory lobuloalveolar units¹³.

Recent high-resolution proteomics and single-cell RNA sequencing (scRNA-Seq) have reshaped our understanding of this phase. While fibroblasts were traditionally viewed as the primary architects of the extracellular

Table 1. Triphasic Regulation of Collagen and Extracellular Matrix Composition Across the Mammary Cycle

Phase	Collagen/ECM Status	Key Features	Functional Consequence	Ref
Pregnancy (Expansion & Preparation)	Fibrillar collagens (types I, III) upregulated; high flexibility, low cross-linking	– Collagen also produced by lymphoid/myeloid immune cells – Enrichment of type VI collagen and SPARC	Accommodates rapid alveologenesis without premature stiffening	[14, 15]
Lactation (Suppression)	Collagen synthesis nearly undetectable around acini	– Basement membrane (laminin, type IV collagen) serves as the primary support Adipocytes undergo lipolysis	Prevents stiff matrix from inhibiting acinar expansion/contraction during milk ejection	[15-18]
Involution (Remodeling)	Massive transient deposition of “involution collagen”; structurally distinct	– Linearized, aligned, and radially oriented fibers (TACS-3) – High LOX activity → increased cross-linking and stiffness – Elevated pro-tumorigenic proteins: osteopontin, tenascin-C, laminin- α 1	Creates a pro-invasive ECM scaffold; promotes tumor cell migration and metastasis; NSAID treatment partially reverses these changes	[15, 33-35]

matrix (ECM), emerging data reveal an ectopic upregulation of fibrillar collagens (Types I and III) by lymphoid and myeloid immune cells, likely facilitating rapid tissue expansion¹⁴. The pregnancy-associated ECM is characterized by high flexibility and low cross-linking, mediated by Type VI collagen and SPARC, optimized to accommodate burgeoning alveoli without the mechanical stiffness often associated with malignancy¹⁵. Enrichment of type VI collagen and the secreted protein acidic and rich in cysteine (SPARC) further suggests a matrix designed for elasticity¹⁵.

Lactation (The Suppression Phase): Lactation represents a state of terminal differentiation where the mammary epithelium is specialized for milk secretion. During this phase, the microenvironment is characterized by a unique metabolic and immune profile that generally suppresses tumorigenesis, although the high metabolic demands of the tissue create a complex metabolic landscape that is still being elucidated. In a remarkable functional shift, collagen synthesis becomes nearly undetectable around the mammary acini during active lactation¹⁵. This suppression is likely a functional requirement for milk production¹⁵. As the mammary acini must cycle between expansion and contraction during nursing, a

dense, stiff collagen matrix would likely inhibit these rapid morphological changes¹⁶.

During this phase, the basement membrane (BM) remains the primary structural support, enriched with laminins and type IV collagen, which are essential for maintaining mammary epithelial cell (MEC) polarity and lactation performance¹⁷. Additionally, adipocytes in the mammary fat pad undergo significant lipolysis to satisfy the high energy demands of milk production, resulting in a reduction of lipid content and a shift in stromal composition¹⁸.

Involution (The Remodeling Phase): Involution is the process by which the lactating gland returns to its non-secretory, quasi-nulliparous state¹⁹. The triphasic regulation of collagen and ECM composition across pregnancy, lactation, and involution is summarized in Table 1. This process occurs in two distinct phases²⁰. Stage 1 (reversible) is triggered by milk engorgement and the accumulation of milk proteins, and is characterized by the phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3) in mammary epithelial cells, leading to lysosomal-mediated cell death²¹. In rodents, if the suckling young are returned within approximately 48 hours, this phase can be reversed and lactation restored²².

Stage 2 (irreversible) ensues if weaning continues; the gland enters an irreversible phase marked by the activation of proteases and extensive structural remodeling²³. This phase involves the breakdown of the basement membrane by matrix metalloproteinases (MMPs) and the clearance of billions of apoptotic mammary epithelial cells by professional phagocytes²⁴. The ECM changes during this second phase are the most dramatic and pro-tumorigenic of the entire cycle, with a massive, transient deposition of “involution collagen” that is structurally distinct from the collagen of pregnancy¹⁵. These changes include the alignment and linearization of collagen fibers, increased lysyl oxidase-mediated cross-linking that elevates tissue stiffness, and the enrichment of pro-invasive proteins such as osteopontin and tenascin-C, collectively generating a microenvironment that facilitates tumor cell invasion.

Postpartum Breast Cancer (PPBC): A Deep Dive into a Distinct Phenotype

PPBC is increasingly recognized as a unique clinical entity with a biology that distinguishes it from other BCs⁴.

Definition and Epidemiology: Historically, PPBC was grouped under the broader category of pregnancy-associated breast cancer (PABC). However, recent evidence suggests that BCs diagnosed after the cessation of lactation have a significantly worse prognosis than those diagnosed during pregnancy²⁵. Current expert consensus defines PPBC as a cancer diagnosed within five to ten years of the most recent childbirth⁴. It is estimated that PPBC may account for up to 50% of BC cases in women under the age of 40²⁶.

Clinical Characteristics and Aggressive Phenotype: The clinical hallmark of PPBC is its high metastatic potential. Patients diagnosed in the early postpartum period (within five years of birth) are nearly three times more likely to develop distant metastasis resulting in death compared to age-matched nulliparous controls²⁷. PPBC is characterized by a higher

proportion of triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-enriched subtypes, larger tumor size at diagnosis, and a higher incidence of lymph node involvement⁵. A distinctive feature of PPBC is its propensity for hepatic (liver) metastasis, with an approximately three-fold increase in liver metastasis observed in postpartum breast cancer patients compared to controls²⁸. Furthermore, these aggressive features translate into significantly worse disease-free and overall survival rates, particularly in node-positive disease⁵.

T-Cell Exhaustion and the "Cold" Tumor Microenvironment: A “cold” tumor microenvironment is characterized by poor infiltration and/or functional inactivation of anti-tumor effector immune cells, particularly CD8⁺ T cells, resulting in an inability to mount an effective immune response against the tumor²⁹. Exhausted T cells, which progressively lose their proliferative capacity, cytokine production, and cytolytic function, are a central feature of such cold tumors and contribute directly to immune evasion and disease progression. Recent studies using GeoMx Digital Spatial Profiling (DSP) have provided a high-resolution view of the PPBC microenvironment. Tumors diagnosed shortly after birth are enriched with markers of T-cell exhaustion, such as Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), Programmed cell death protein 1 (PD-1), and Granzyme B (GZMB)¹⁰. This transcriptomic signature of non-responsive T-cells suggests that the involution microenvironment actively inhibits the host's ability to orchestrate an effective anti-tumor immune response³⁰. Furthermore, the immune checkpoint B7 homolog 4 (B7-H4), which is upregulated by progesterone during pregnancy to maintain fetal tolerance, may be hijacked by emerging breast tumors to evade surveillance³¹.

How Physiological Phases Prime Pathogenesis

The high aggressiveness of PPBC is not an intrinsic property of the cancer cells alone, but

a result of the cells "mimicking" or hijacking the normal developmental programs of involution¹¹. The key ECM components, enzymatic drivers, and their pro-tumorigenic consequences are detailed in Table 2.

The Involution ECM as a Scaffold for Invasion: In rodent models, "involution collagen" deposited after weaning may serve as a structural "highway" facilitating cancer cell migration. Unlike the wavy fibers of the

Table 2. Extracellular Matrix Dynamics and Pro-Tumorigenic Remodeling in the Postpartum Mammary Gland

Phase / Context	ECM Component / Feature	Key Regulation / Enzyme	Pro-Tumorigenic Consequence	Ref
Pregnancy	Fibrillar collagens I & III (also produced by immune cells)	Upregulated by estrogen/progesterone; also secreted by lymphoid/myeloid cells	Low cross-linking and high elasticity accommodate alveologenesi without premature stiffening	[14, 15]
	Type VI collagen, SPARC	Enriched in pregnancy-associated ECM	Supports matrix flexibility and secretory unit expansion	[15]
Lactation	Basement membrane proteins: laminin, type IV collagen	Collagen synthesis is suppressed; BM remains the primary structural support	Maintains MEC polarity and lactation performance; prevents stiff matrix from inhibiting acinar cycling	[15-18]
Involution (physiological)	"Involution collagen" (fibrillar)	Transient massive deposition; structurally distinct from pregnancy collagen	Acts as a scaffold for tumor cell migration ("highway"); linearized, aligned, radially oriented fibers (TACS-3)	[15]
	Collagen packing density and fiber alignment	SHG imaging reveals higher packing density; TACS-3 signature	TACS-3 is an independent poor prognostic factor that facilitates collective cell invasion	
	Lysyl oxidase (LOX)	Peak expression during mid-involuti on	Increases collagen cross-linking and tensile strength → matrix stiffness linked to malignant transformation and therapy resistance	[33, 34]
	Osteopontin, tenascin-C, laminin-α1	Upregulated in involuti ng ECM (proteomics)	Fail to support normal ductal organization; promote tumor cell invasion	
Involuti on (functional consequence)	Proteolyzed collagen fragments	Increased fibrillar collagen proteolysis	Act as chemoattractants for macrophages, amplifying the tumor-promotional milieu	[9]
	Whole ECM from the involuti ng gland	Isolated ECM promotes invasiveness in vitro	In vivo: increases metastasis to the lung, liver, and kidney compared to nulliparous ECM	[34]
Enzymatic remodeling	MMP-9	Highly sensitive to reproductive state; degrades basement membrane; produced by macrophage–adipose stromal cell interactions	Creates a "leaky" microenvironment that supports angiogenesis and tumor cell proliferation	[23, 36] [37]
Therapeutic modulation	NSAIDs (ibuprofen)	Reduce collagen fibrillogenesis; decrease tenascin-C and laminin levels	Attenuate the tumor-promotional attributes of involuti ng ECM; evidence for prophylactic intervention	[33, 35]
Environmental exposures	Collagen I, laminin (DES)	In utero DES → early collagen depletion followed by pubertal surge	Increased matrix density and altered fiber orientation → permanently susceptible microenvironment	[45]
	Water and collagen content (PAHs)	PAH–tobacco smoke interaction during pregnancy	Altered breast tissue composition may influence mammographic density and lifetime cancer risk	[47]

nulliparous gland, involution-associated collagen is linearized and aligned, with fibers that are straighter and more tightly packed, as demonstrated by second harmonic generation (SHG) imaging, revealing higher collagen packing density during involution compared to nulliparous and lactating glands¹⁵. These fibers are radially oriented, with many positioned perpendicular to the mammary epithelium, a signature known as Tumor-Associated Collagen Signature-3 (TACS-3); an architecture that in human breast cancer facilitates collective cell invasion and is a well-established poor prognostic factor¹⁵. Additionally, in rodent involuting glands, tissue stiffness increases significantly during mid-involution due to peak expression of lysyl oxidase (LOX), which mediates collagen cross-linking and is associated with increased levels of cross-linked collagen¹⁵. Increased matrix stiffness has been associated with malignant transformation and therapeutic resistance in experimental models³². Proteomic analyses of rodent involuting ECM have further identified compositional changes in the involuting ECM, including increases in pro-tumorigenic proteins such as osteopontin, tenascin-C, and laminin- α 1, which collectively contribute to a microenvironment that fails to support normal ductal organization while actively promoting tumor cell invasion^{33, 34}. Functionally, ECM isolated from involuting mammary glands promotes invasiveness in tumor cells and increases metastasis to the lung, liver, and kidney *in vivo* compared to ECM from nulliparous glands³⁴. The ECM remodeling process also involves increased proteolysis of fibrillar collagen, generating bioactive fragments that act as chemoattractants for macrophages, which in turn contribute to the tumor-promotional milieu⁹. Importantly, in rodent models, nonsteroidal anti-inflammatory drug (NSAID) treatment during involution has been shown to reduce collagen fibrillogenesis, decrease tenascin-C and laminin levels, and attenuate the tumor-promotional attributes of the involuting ECM, providing preclinical

evidence for potential therapeutic intervention targeting this matrix-driven pathway^{33,35}. Together, these coordinated changes in collagen architecture, alignment, cross-linking, composition, and stiffness create a uniquely permissive ECM that facilitates invasion and metastatic dissemination in the postpartum mammary gland, providing a mechanistic explanation for the high rate of metastases observed in PPBC (Table 1 and 2)^{15,34}.

Enzymatic Drivers and the "Leaky"

Environment: The enzymatic restructuring required to regress the lactating gland can inadvertently facilitate tumor spread. In rodent mammary glands, MMP-9, which is highly sensitive to the reproductive state, is essential for degrading the basement membrane during involution²³. In bovine models, exogenous MMP-9 administration accelerates involution³⁶. In *in vitro* co-culture models using human macrophages and adipose stromal cells, elevated MMP-9 levels may contribute to a microenvironment that favors angiogenesis and tumor cell proliferation (Table 2)³⁷.

Macrophage Re-education and Immune

Suppression: In the rodent model, the massive influx of F4/80-expressing macrophages during involution is necessary to clear billions of apoptotic MECs through efferocytosis (the phagocytic clearance of apoptotic cells)³⁰. However, this intensive wound-healing activity re-educates macrophages toward an M2-like, alternatively activated phenotype⁹. These "involution macrophages" cooperate with adipose stromal cells to secrete pro-inflammatory and angiogenic cytokines, such as interleukin 6 (IL-6), C-X-C motif chemokine ligand 1 (CXCL1), C-X-C motif chemokine ligand 5 (CXCL5), and monocyte chemoattractant protein-1 (MCP-1)³⁷. This milieu is believed to suppress anti-tumor immunity and supply growth factors that could support the expansion of occult tumor cells, at least in murine models³⁸.

Despite the compelling evidence linking postpartum involution to breast cancer

progression, not all studies have observed a uniform risk increase. Some population-based analyses found that the excess metastasis risk is largely confined to women diagnosed within 2-5 years of delivery and is less pronounced in certain molecular subtypes, suggesting that involution-associated risk may be time- and subtype-dependent²⁷. Furthermore, prolonged lactation itself exerts a long-term protective effect against breast cancer, indicating that the reproductive cycle contains both transient adverse and lasting beneficial windows. These nuances highlight the need for further investigation into the factors that tip the balance from tissue repair to tumor promotion. In contrast, a pooled analysis of 15 prospective cohorts reported only a modest, transient elevation in breast cancer risk following childbirth, an effect substantially attenuated by prolonged breastfeeding². These discrepancies likely reflect differences in postpartum window definitions, tumor subtype distributions, and the use of rodent models with acute synchronized involution versus the more gradual and heterogeneous human process.

Immune Remodeling as a Bridge to Tumor Progression: The postpartum involution microenvironment is now understood to orchestrate a coordinated immunosuppressive program that simultaneously disarms anti-tumor immunity and provides trophic support for malignant cells. Central to this program is the functional coupling between M2-like macrophages and exhausted T cells.

Involution-associated macrophages, reprogrammed toward an alternatively activated phenotype by efferocytosis and local cytokine cues, secrete IL-6, IL-10, transforming growth factor-beta (TGF- β), and C-C motif chemokine ligand 2 (CCL2), which not only suppress cytotoxic T-cell activity but also reinforce the exhausted T-cell state characterized by sustained PD-1, CTLA-4, and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression^{9,10,30,37}. Concurrently, the loss of

mature dendritic cell function and the predominance of regulatory T cells further dampen adaptive immune surveillance^{30,38}. This immune landscape mirrors the “cold” tumor microenvironment described above, and is thought to provide a permissive niche for the outgrowth of occult tumor cells.

Preclinical evidence suggests that disrupting these immunosuppressive circuits can reduce postpartum tumor progression. In rodent models, NSAID-mediated dampening of the wound-healing inflammatory response reduces M2 macrophage recruitment and collagen remodeling^{33,35}; Blockade of colony-stimulating factor 1 receptor (CSF-1R) signaling depletes involution macrophages and attenuates metastasis⁶; and immune checkpoint inhibition (anti-programmed death 1 [PD-1]/anti-programmed death-ligand 1 [PD-L1]) partially restores T-cell function in postpartum mammary tumors⁶. Although these strategies remain confined to experimental models, they collectively identify macrophage re-polarization, cytokine neutralization (such as anti-IL-6), and checkpoint blockade as rational targets for future clinical investigation in postpartum breast cancer.

Molecular Regulatory Nodes and Environmental Programming

Expert-level understanding of this field requires examining the fine-tuned molecular switches that govern these transitions.

MicroRNAs as Bioreporters and Regulators: MicroRNAs (miRNAs) serve as critical post-transcriptional regulators of mammary function. In terms of lactation performance, human milk levels of let-7g-5p have been identified as bioreporters, with high levels associated with low milk supply and early cessation of breastfeeding, likely through downregulation of the prolactin receptor (PRLR)³⁹. Furthermore, miRNAs such as miR-148a and the miR-200 family directly regulate prolactin signaling and epithelial differentiation during lactation; miR-148a suppresses PRLR expression, while miR-200

family members enforce the luminal epithelial phenotype, and their coordinated downregulation during weaning facilitates secretory de-differentiation. Regarding persistent risks, research using murine models shows that forced or abrupt weaning leads to a persistent downregulation of tumor-suppressive miRNAs, such as miR-143 and miR-145, which remain low even after full tissue regression⁴⁰. This sustained suppression suggests that a lack of gradual weaning may maintain a pro-carcinogenic environment long-term⁴⁰. Conversely, the miR-424(322)/503 cluster is transiently upregulated during the involution phase, where it targets key regulators of apoptosis and adipogenesis (including BCL2 and FGFR1), thereby coordinating epithelial clearance and stromal repopulation⁴¹; persistent dysregulation of this cluster may similarly contribute to the pro-tumorigenic remodeling of the postpartum gland. Together, these findings highlight a tightly orchestrated miRNA network that governs the successive phases of mammary remodeling, with perturbations in these circuits potentially tipping the balance toward postpartum breast cancer progression.

Calpain-2 and Inflammation: The murine model of weaning significantly impacts the local inflammatory response. Abrupt weaning induces a spike in Calpain-2 activity and acute inflammation, whereas spontaneous or gradual weaning maintains a milder inflammatory environment⁴⁰. In murine models, higher Calpain-2 expression in the short lactation model persisted for up to 28 days postpartum, highlighting how weaning patterns can "program" the mammary gland⁴⁰. The inflammation driven by abrupt weaning and calpain-2 activation may feed into multiple downstream pathways, including those controlled by C/EBP β , a transcription factor that integrates inflammatory and developmental signals.

The LIP/LAP Ratio of C/EBP β : The transcription factor C/EBP β is a master

regulator of mammary development and tissue remodeling⁴². It is translated into three isoforms: liver-enriched transcriptional activator protein 1 (LAP1), liver-enriched transcriptional activator protein 2 (LAP2), and liver-enriched transcriptional inhibitory protein (LIP). An aberrantly high LIP/LAP ratio, driven by pathways such as HER2 or TGF β , is a hallmark of high-grade, hormone-receptor-negative breast cancers⁴³. This ratio promotes the epithelial-to-mesenchymal transition (EMT) and matrix invasion, directly linking intracellular signaling to the pro-tumorigenic ECM⁴⁴. In the context of PPBC, the involution microenvironment provides a rich source of TGF β (liberated from the remodeled ECM and secreted by M2-like macrophages) that further amplifies LIP expression^{43,44}. The resulting LIP-dependent EMT program synergizes with involution-associated ECM stiffening and aligned collagen fibers to enhance tumor cell motility and invasion, thereby contributing to the heightened metastatic burden, including the hepatic metastasis characteristic of PPBC. Thus, the LIP/LAP axis may represent a convergent node where developmental inflammatory signals and matrix remodeling co-opt a transcriptional switch that drives the uniquely aggressive biology of postpartum breast cancer.

Environmental Influences: Maternal health and BC risk are also shaped by environmental exposures during critical windows of susceptibility. In the case of endocrine-disrupting compounds, a mouse study showed that in utero exposure to the synthetic estrogen diethylstilbestrol (DES) can reprogram the mammary gland. This occurs through an early depletion of fibrillar collagens, followed by a subsequent surge in collagen I and laminin during puberty. These alternations lead to greater matrix density and changes in fiber orientation by adulthood, ultimately generating a tissue microenvironment that remains more susceptible to later pathological changes⁴⁵.

Similarly, gestational and lactational exposure to bisphenol A (BPA) has been shown to induce spontaneous mammary carcinomas in aged gerbils, strengthening the association between developmental endocrine disruption and malignancy driven by tissue remodeling⁴⁶. Regarding ambient polycyclic aromatic hydrocarbons (PAHs), exposure to these air pollution-derived compounds during pregnancy may interact synergistically with tobacco smoke, leading to changes that significantly affect water and collagen content and influence mammographic density and lifetime cancer risk (Table 2)⁴⁷.

Clinical Perspectives: The Path Forward for Maternal Health

ECM Remodeling, Translational Insights: The identification of the “involution collagen” signature (linearized, aligned fibers, LOX-mediated cross-linking, and TACS-3 architecture) provides a structural rationale for the high metastatic propensity of PPBC. Most of this evidence derives from rodent models and ex vivo human tissue imaging^{15,34}; direct demonstration that these ECM changes alone drive human metastasis is still lacking. Nonetheless, the finding that NSAIDs can attenuate collagen fibrillogenesis and reduce tenascin-C and laminin levels in involuting rodent glands^{33,35} has generated considerable interest. It is important to emphasize that evidence for NSAID prophylaxis remains preclinical; no human trial has evaluated the safety or efficacy of NSAIDs during involution for breast cancer prevention, and NSAID use during lactation must consider potential risks to the infant. In parallel, the time since last birth (TSLB) is emerging as a robust, readily available prognostic biomarker in premenopausal breast cancer, supported by multiple observational cohort studies¹⁰, although its formal integration into risk-stratification tools requires prospective validation.

Immune Reprogramming, Translational Insights: The postpartum immune milieu (dominated by M2-like macrophages,

exhausted T cells, and suppressive cytokines such as IL-6 and TGF- β) represents an attractive therapeutic target. In rodent models, NSAID-mediated dampening of the wound-healing response reduces M2 macrophage recruitment and collagen remodeling^{33,35}, while CSF-1R blockade depletes involution macrophages and attenuates metastasis⁶. Immune checkpoint inhibition (anti-PD-1/PD-L1) has shown partial restoration of T-cell function in postpartum mammary tumor models⁶. These strategies remain strictly experimental, and no clinical studies have yet evaluated immunomodulation specifically in the postpartum setting. Nevertheless, they highlight macrophage re-polarization, cytokine neutralization, and checkpoint blockade as rational areas for future clinical investigation.

Knowledge Gaps and Future Directions:

Several critical questions remain unanswered. First, direct causal evidence linking involution-associated ECM remodeling and immune suppression to human breast cancer initiation or progression is limited; most findings originate from genetically engineered mouse models or observational cohorts. Second, the optimal biomarker panel for postpartum-specific risk assessment (potentially combining TSLB, circulating ECM fragments, and immune profiling) has not been defined. Third, the long-term impact of weaning practices (abrupt in comparison with gradual) and lactation duration on ECM and immune reprogramming in women is unknown and warrants a prospective study. Fourth, while preclinical data support NSAID intervention, the timing, dose, and safety in lactating women need formal evaluation. Finally, whether the LIP/LAP axis or MMP-9 can be therapeutically targeted in postpartum patients remains purely speculative.

In summary, the postpartum mammary gland is a unique biological landscape where normal tissue involution creates a transient pro-tumorigenic niche through aligned, stiffened ECM and an immunosuppressive

microenvironment. While preclinical models have illuminated the key cellular and molecular players (LOX-crosslinked collagen, M2 macrophages, exhausted T cells), their translation to human clinical practice remains in its infancy. The time since last birth already serves as a practical prognostic marker, and NSAIDs, CSF-1R blockade, and immune checkpoint inhibitors offer promising but unproven avenues for intervention. Future research must bridge the gap between rodent models and human biology through carefully designed prospective studies and clinical trials. By addressing these gaps, we can move toward personalized screening and therapeutic strategies that reduce the burden of postpartum breast cancer and safeguard maternal health.

Conclusion

The postpartum mammary gland is a landscape of profound biological change. Recent studies have elevated our understanding from a focus on the mammary epithelium to a holistic view of the extracellular matrix-immune cell-hormone axis. The involution process, through aligned and crosslinked collagen deposition driven by MMPs and LOX, together with the emergence of an M2-like macrophage and exhausted T-cell milieu, creates a uniquely permissive environment for tumor cell invasion and metastasis. The postpartum period is therefore a window of physiological vulnerability where the necessary processes of tissue regression may be hijacked by emerging tumor cells. Critical knowledge gaps remain: direct causal evidence linking involution-associated remodeling to human breast cancer is scarce, the optimal biomarker panel for postpartum-specific risk stratification is undefined, and the long-term impact of weaning strategies and lactation duration on immune and ECM reprogramming requires prospective human studies. From a translational perspective, the time since last birth represents a readily available prognostic biomarker, while the postnatal use of NSAIDs to dampen the wound-healing response and the targeting of the LIP/LAP or CSF-1R axes are

promising therapeutic avenues that now warrant clinical evaluation. By recognizing that collagen is under reproductive control, that immune cells contribute to this matrix induction, and that involution triggers a state of immune exhaustion, clinicians and researchers can begin to solve the “postpartum paradox” through personalized screening and therapeutic innovation, ultimately safeguarding the health of mothers globally.

Conflict of Interest

Authors have no conflict of interests.

Acknowledgments

Not applicable.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not for profit sectors.

Ethical Considerations

Not applicable.

Author's Contribution

Samane Heydari: Conceptualization, investigation, writing – original draft, writing – review & editing, visualization. Sadegh Safaei: Writing – review & editing.

How to Cite: Heydari s, Safaei s. Dynamic Extracellular Matrix Remodeling and Immune Reprogramming in the Postpartum Mammary Gland: Implications for Maternal Health and Breast Cancer Risk. *World J Peri & Neonatol* 2025; 8(1): 13-25.
DOI: 10.18502/wjpn.v8i1.21580

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2024; 74(3): 229-63.
2. Nichols HB, Schoemaker MJ, Cai J, Xu J, Wright LB, Brook MN, et al. Breast Cancer Risk After Recent Childbirth: A Pooled

- Analysis of 15 Prospective Studies. *Ann Intern Med* 2019; 170(1): 22-30.
3. Mathews TJ, Hamilton BE. Mean Age of Mothers is on the Rise: United States, 2000-2014. *NCHS Data Brief* 2016; (232): 1-8.
 4. Jindal S, Pennock ND, Sun D, Horton W, Ozaki MK, Narasimhan J, et al. Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. *Nat Commun* 2021; 12(1): 6341.
 5. Nimbalkar VP, Snijesh VP, Rajarajan S, Alexander A, Kaluve R, Ramesh R, et al. Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis. *Breast Cancer Res Treat* 2023; 200(1): 139-49.
 6. Fornetti J, Martinson HA, Betts CB, Lyons TR, Jindal S, Guo Q, et al. Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. *J Mammary Gland Biol Neoplasia* 2014; 19(2): 213-28.
 7. Watson CJ, Khaled WT. Mammary development in the embryo and adult: new insights into the journey of morphogenesis and commitment. *Development* 2020; 147(22): dev169862.
 8. Jindal S, Narasimhan J, Borges VF, Schedin P. Characterization of weaning-induced breast involution in women: implications for young women's breast cancer. *NPJ Breast Cancer* 2020; 6: 55.
 9. O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. *Am J Pathol* 2010; 176(3): 1241-55.
 10. Sherman ME, Etievant L, Vierkant RA, Winham SJ, Ruddy KJ, Pacheco-Spann L, et al. Postpartum breast cancer: evidence for a distinct phenotype. *J Natl Cancer Inst* 2026; 118(5): 926-36.
 11. Valdés-Mora F, Salomon R, Gloss BS, Law AMK, Venhuizen J, Castillo L, et al. Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype. *Cell Rep* 2021; 35(2): 108945.
 12. Arendt LM, Kuperwasser C. Form and function: how estrogen and progesterone regulate the mammary epithelial hierarchy. *J Mammary Gland Biol Neoplasia* 2015; 20(1-2): 9-25.
 13. Macias H, Hinck L. Mammary gland development. *Wiley Interdiscip Rev Dev Biol* 2012; 1(4): 533-57.
 14. Yamaguchi K, Nakayama J, Yamamoto T, Semba K, Shiota T, Yamamoto Y. Collagen induction of immune cells in the mammary glands during pregnancy. *Physiol Genomics* 2024; 56(2): 128-35.
 15. Guo Q, Sun D, Barrett AS, Jindal S, Pennock ND, Conklin MW, et al. Mammary collagen is under reproductive control with implications for breast cancer. *Matrix Biol* 2022; 105: 104-26.
 16. Melcher ML, Block I, Kropf K, Singh AK, Posern G. Interplay of the transcription factor MRTF-A and matrix stiffness controls mammary acinar structure and protrusion formation. *Cell Commun Signal* 2022; 20(1): 158.
 17. Warburton MJ, Mitchell D, Ormerod EJ, Rudland P. Distribution of myoepithelial cells and basement membrane proteins in the resting, pregnant, lactating, and involuting rat mammary gland. *J Histochem Cytochem* 1982; 30(7): 667-76.
 18. Zwick RK, Rudolph MC, Shook BA, Holtrup B, Roth E, Lei V, et al. Adipocyte hypertrophy and lipid dynamics underlie mammary gland remodeling after lactation. *Nat Commun* 2018; 9(1): 3592.
 19. Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. *J Mammary Gland Biol Neoplasia* 2007; 12(1): 25-35.
 20. Baxter FO, Neoh K, Tevendale MC. The beginning of the end: death signaling in early involution. *J Mammary Gland Biol Neoplasia* 2007; 12(1): 3-13.
 21. Hughes K, Watson CJ. The Multifaceted Role of STAT3 in Mammary Gland Involution and Breast Cancer. *Int J Mol Sci* 2018; 19(6): 1695.
 22. Mironov A, Fisher M, Narayanan P, Elsayed R, Karabulutoglu M, Akhtar N. Rac1 controls cell turnover and reversibility of the involution process in postpartum mammary glands. *PLoS Biol* 2023; 21(1): e3001583.
 23. Werb Z, Ashkenas J, MacAuley A, Wiesen JF. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and

- carcinogenesis. *Braz J Med Biol Res* 1996; 29(9): 1087-97.
24. Hanayama R, Nagata S. Impaired involution of mammary glands in the absence of milk fat globule EGF factor 8. *Proc Natl Acad Sci U S A* 2005; 102(46): 16886-91.
25. Lefrère H, Floris G, Schmidt MK, Neven P, Warner E, Cardonick E, et al. Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. *Eur J Cancer* 2021; 155: 13-24.
26. Lefrère H, Lenaerts L, Borges VF, Schedin P, Neven P, Amant F. Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. *Int J Gynecol Cancer* 2021; 31(3): 412-22.
27. Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. *Breast Cancer Res Treat* 2013; 138(2): 549-59.
28. Goddard ET, Hill RC, Nemkov T, D'Alessandro A, Hansen KC, Maller O, et al. The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis. *Cancer Discov* 2017; 7(2): 177-87.
29. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. *Science* 2015; 348(6230): 74-80.
30. Hitchcock J, Hughes K, Pensa S, Lloyd-Lewis B, Watson CJ. The immune environment of the mammary gland fluctuates during post-lactational regression and correlates with tumour growth rate. *Development* 2022; 149(8): dev200162.
31. Yu J, Yan Y, Li S, Xu Y, Parolia A, Rizvi S, et al. Progesterone-driven B7-H4 contributes to onco-fetal immune tolerance. *Cell* 2024; 187(17): 4713-32.e19.
32. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell* 2009; 139(5): 891-906.
33. O'Brien JH, Vanderlinden LA, Schedin PJ, Hansen KC. Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis. *J Proteome Res* 2012; 11(10): 4894-905.
34. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, et al. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. *Am J Pathol* 2006; 168(2): 608-20.
35. Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. *Nat Med* 2011; 17(9): 1109-15.
36. Parés S, Cano-Garrido O, Bach A, Ferrer-Mirallès N, Villaverde A, García-Fruitós E, et al. The Potential of Metalloproteinase-9 Administration to Accelerate Mammary Involution and Boost the Immune System at Dry-Off. *Animals (Basel)* 2021; 11(12): 3415.
37. Doyle M, Kwami N, Joshi J, Arendt LM, McCready J. Interaction between Macrophages and Adipose Stromal Cells Increases the Angiogenic and Proliferative Potential of Pregnancy-Associated Breast Cancers. *Cancers (Basel)* 2023; 15(18): 4500.
38. Martinson HA, Jindal S, Durand-Rougely C, Borges VF, Schedin P. Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. *Int J Cancer* 2015; 136(8): 1803-13.
39. Hicks SD, Chandran D, Confair A, Ward A, Kelleher SL. Human Milk-Derived Levels of let-7g-5p May Serve as a Diagnostic and Prognostic Marker of Low Milk Supply in Breastfeeding Women. *Nutrients* 2023; 15(3): 567.
40. Puebla S, Gimeno A, Ortíz-Zapater E, Zaragoza R, Viña JR, García-Trevijano ER. The Length of Lactation and Model of Weaning Modulate Key Regulatory Nodes of Murine Mammary Gland Involution. *Int J Mol Sci* 2025; 26(21): 10501.
41. Llobet-Navas D, Rodríguez-Barrueco R, Castro V, Ugalde AP, Sumazin P, Jacob-Sendler D, et al. The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. *Genes Dev* 2014; 28(7): 765-82.
42. Spike AJ, Rosen JM. C/EBPβ Isoform Specific Gene Regulation: It's a Lot more Complicated than you Think! *J Mammary Gland Biol Neoplasia* 2020; 25(1): 1-12.
43. Arnal-Estapé A, Tarragona M, Morales M, Guiu M, Nadal C, Massagué J, et al. HER2

- silences tumor suppression in breast cancer cells by switching expression of C/EBP β isoforms. *Cancer Res* 2010; 70(23): 9927-36.
44. Sterken BA, Ackermann T, Müller C, Zuidhof HR, Kortman G, Hernandez-Segura A, et al. C/EBP β isoform-specific regulation of migration and invasion in triple-negative breast cancer cells. *NPJ Breast Cancer* 2022; 8(1): 11.
 45. Tovar-Parra D, McDermott A, Cardot J, Juarez MN, Joao F, El Omri-Charai R, et al. An in utero exposure to the synthetic estrogen diethylstilbestrol affects the fat pad composition in post-natal mammary glands. *Toxicol Sci.* 2026;209(1).
 46. Ruiz TFR, Colleta SJ, Leonel ECR, Taboga SR. Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation. *Endocr Relat Cancer* 2021; 28(11): 715-30.
 47. Kehm RD, Walter EJ, Oskar S, White ML, Tehranifar P, Herbstman JB, et al. Exposure to polycyclic aromatic hydrocarbons during pregnancy and breast tissue composition in adolescent daughters and their mothers: a prospective cohort study. *Breast Cancer Res.* 2022; 24(1): 47.